Trial Profile
A clinical study to compare efficacy and safety of infliximab biosimilar (IB) and infliximab bio-original (IO) in rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis; Spondylarthritis
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2018 New trial record
- 07 Jun 2018 Results assessing survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) were published in the Clinical and Experimental Rheumatology